Aerovate Therapeutics, Inc. (AVTE) Misses Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts AVTE Hot Sheet
Join SI Premium – FREE
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) reported Q2 EPS of ($0.49), $0.04 worse than the analyst estimate of ($0.45).
For earnings history and earnings-related data on Aerovate Therapeutics, Inc. (AVTE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI and memory not a classic bubble, but future returns uncertain - strategist
- Needham remains cautious on Nike stock, sees more downside risk
- BlackBerry (BB) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
